Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RXC004 monotherapy and RXC004 + nivolumab in RNF43/RSPO-aberrated metastatic microsatellite-stable colorectal cancer
2020-003132-24Phase 2Completed
- Sponsor
- Redx Pharma
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of zamaporvint and nivolumab in colorectal cancer (CRC) (2 arms), sponsored by Redx Pharma. Primary endpoint: Disease control rate. Started Jul 2021; status: completed.
02
Drugs
zamaporvintnivolumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2020-003132-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003132-24.